It binds to the BH3 domain of BCL2 with subsequent release of sequestered BH-3-only proteins, thereby triggering BAX/BAK-mediated rapid tumor-cell death and anti-tumor activity [3–8]. This evidence concerns the gene BCL2 and neoplasm.